To the full analysis
LifeStance Health Group stock: growth
LFSTLifeStance Health Group reported $1.42B in revenue for fiscal 2025, up 13.9% on the prior year, up 30.4% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
37.3%
per year from 2019 to 2025, per share 36.6%
Earnings (Annual rate)
9.3%
per year from 2019 to 2025
Free cash flow (Annual rate)
85.1%
per year from 2019 to 2025, per share 84.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 30.4% | 37.3% |
| Revenue per share | 29.6% | 36.6% |
| Earnings | no data | 9.3% |
| Earnings per share | no data | no data |
| Free cash flow | no data | 85.1% |
| Free cash flow per share | no data | 84.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $212.52M | $5.67M | $2.73M |
| 2020 | $377.22M | −$38.07M | −$46.6M |
| 2021 | $667.51M | −$307.2M | −$85.07M |
| 2022 | $859.54M | −$215.56M | −$26.47M |
| 2023 | $1.06B | −$186.26M | −$57.4M |
| 2024 | $1.25B | −$57.44M | $85.69M |
| 2025 | $1.42B | $9.66M | $110.03M |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.